Petosemtamab: Clinical Trials

3 recruiting, 2 active not recruiting. 4 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	4	Active not recruiting 2, Recruiting 2
Phase 1	1	Recruiting 1
Phase 2	1	Recruiting 1

Follow Petosemtamab: new trials by email Literature Review of Petosemtamab trials Research Report on Petosemtamab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer	Phase 3	Recruiting	Genmab	600	2026-10-07	2026-11-12
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer	Phase 3	Recruiting	Genmab	960	2026-08-11	2026-11-03
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) Petosemtamab, Pembrolizumab - Head and Neck Squamous Cell Carcinoma	Phase 3	Active not recruiting	Genmab	699	2024-09-25	2026-11-02
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) Petosemtamab, Investigator's Choice - Head and Neck Squamous Cell Carcinoma	Phase 3	Active not recruiting	Genmab	621	2024-06-25	2026-11-12
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI - Advanced/Metastatic Solid Tumors, Colorectal Cancer	Phase 1 / Phase 2	Recruiting	Genmab	560	2018-05-02	2026-11-02

Conditions studied

Squamous Cell Carcinoma of Head and Neck (3)  ·  Colorectal Neoplasms (2)  ·  Esophageal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Laryngeal Diseases (1)  ·  Stomach Neoplasms (1)

Sponsors

Genmab (5)

Countries

United States (5)  ·  Australia (3)  ·  Belgium (3)  ·  France (3)  ·  Italy (3)  ·  Netherlands (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Argentina (2)  ·  Brazil (2)  ·  Canada (2)  ·  Chile (2)  ·  Czechia (2)  ·  Germany (2)  ·  Greece (2)

Results publications

PMID 40511820

NIH funding

2023 (2), 2017 (1)